Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” ...

Buying Alexion remains a “fantastic acquisition” for AstraZeneca, the Big Pharma’s CEO has said, even as the company takes a ...

AstraZeneca’s rare disease firm Alexion is set to expand its genomic medicine portfolio with the acquisition of gene editing specialist LogicBio Therapeutics, in a deal worth approximately $68 ...

Alexion has routinely featured ... and that was a good call – AstraZeneca has just swooped in with $39 billion cash-and-stock takeover offer. The deal – the largest in the pharma sector ...

Shares of the British-Swedish pharmaceutical titan AstraZeneca are trading 7% lower in London today as investors price in the acquisition of Alexion Pharmaceuticals for $39 billion. A deal, which is ...

Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...

The turning point that altered the trajectory of its stock price was the company's agreement with Alexion, AstraZeneca Rare Disease for ALXN-1840, signed on October 24, 2024. Monopar shares soared ...

AstraZeneca has terminated all development of vemircopan, the oral factor D inhibitor it acquired through the deal for ...

AstraZeneca’s planned vaccine hub for Liverpool is off the table - business editor Karl Matchett and Whitehall editor Kate ...